Trials in Progress in Non-Muscle Invasive Bladder Cancer

CORE-008 Cohort B Evaluates Cretostimogene in BCG-Exposed Non-Muscle Invasive Bladder Cancer - Trinity Bivalacqua

Translational Insights for Cretostimogene Grenadenorepvec for BCG-Naïve Bladder Cancer - Trinity Bivalacqua

CORE-008 Cohort A: Evaluates Cretostimogene in BCG‑Naive High‑Risk NMIBC - Shreyas Joshi

BOND-003 Cohort C: Durability of Responses Examined with Cretostimogene in BCG-Unresponsive Bladder Cancer - Shreyas Joshi

CORE-008 Cohort A First Results on Cretostimogene Grenadenorepvec for BCG-Naive Bladder Cancer - Shane Pearce

Design and Safety of a Patient-Centric Expanded Access Program with Cretostimogene Grenadenorepvec - Sarah Psutka

Cohort P Data from the BOND-003 Study in BCG-Unresponsive Papillary Bladder Cancer - Mark Tyson

24-Month Follow-Up Data from Phase 3 BOND-003 Cohort C Trial - Mark Tyson

CORE-008 Cohort B Investigates Cretostimogene Grenadenorepvec for BCG-Exposed High-Risk NMIBC - Trinity Bivalacqua

Phase 3 Trial Results for Intravesical Cretostimogene Grenadenorepvec in Bladder Cancer - Mark Tyson

Cretostimogene Expanded Access Program Provides Alternative for BCG-Unresponsive Bladder Cancer Patients - Wassim Kassouf

Sasanlimab Plus BCG Improves Event-Free Survival in High-Risk NMIBC: First Interim Trial Results, Journal Club - Rashid Sayyid & Zachary Klaassen

PIVOT-006 Trial: Cretostimogene Grenadenorepvec for Intermediate-Risk Non-Muscle Invasive Bladder Cancer - Max Kates

CORE-008 Trial Cohort CX: Combining Cretostimogene Grenadenorepvec and Gemcitabine for Bladder Cancer - Trinity Bivalacqua

CORE-008 Cohort B: Cretostimogene for BCG-Exposed NMIBC – Trial Activation & Clinical Goals - Trinity Bivalacqua

BOND-003 Cohort P Results for BCG-Unresponsive Papillary Bladder Tumors - Mark Tyson

CORE-008 Cohort A: Cretostimogene in BCG-Naïve High-Risk NMIBC – Trial Design & Update - Trinity Bivalacqua

BOND-003 Cohort C Trial Results for Cretostimogene Grenadenorepvec in BCG-Unresponsive Bladder Cancer - Mark Tyson

PIVOT-006: Phase III Trial of Creto vs Surveillance in Intermediate-Risk Bladder Cancer - Mark Tyson

Cretostimogene Grenadenorepvec: A Novel Oncolytic Immunotherapy for BCG-Unresponsive NMIBC - Roger Li

CORE-001 Study Demonstrates Promising Results for Bladder Cancer with Cretostimogene Grenadenorepvec and Pembrolizumab - Trinity Bivalacqua & Roger Li

PIVOT-006: Phase 3 Trial Comparing Oncolytic Virus Creto vs Observation for Intermediate-Risk NMIBC - Robert Svatek

BOND-003 Trial: Cretostimogene Grenadenorepvec Shows Promise in BCG-Unresponsive NMIBC - Mark Tyson

Breaking Paradigms: BOND-003's Cretostimogene Monotherapy for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Mark Tyson

Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC: A Discussion on the BOND-003 and CORE1 Trials - Trinity Bivalacqua

PIVOT-006 - A Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of Patients with Intermediate-Risk, Non-Muscle Invasive Bladder Cancer - Mark Tyson

BOND-003 Phase 3 Results: Revolutionizing Bladder Cancer Treatment with Intravesical Cretostimogene Grenadenorepvec Monotherapy for High-Risk BCG-Unresponsive NMIBC - Mark Tyson

Cretostimogene Grenadenorepvec Therapy Aims to Fill an Unmet Need in the Bladder Cancer Armamentarium - Robert Svatek

Gene Therapy for Non-muscle Invasive Bladder Cancer - Roger Li

Combining CG0070 Adenovirus Vector with Immune Checkpoint Blockade: Promising Results for BCG Unresponsive Bladder Cancer Patients - Roger Li